Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Connor J R FosterThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Jasper DuThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0003-4156-8949
Oscar PundelThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Mitchell J GeerThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Ryan C RipertThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Jia LiuThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0003-3612-6089
Taylor A HeimThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Kiyomi Y ArakiThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Amanda W LundThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
Jun WangThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0002-6346-2929
Benjamin G NeelThe Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.ORCID 0000-0002-9589-585X
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
MEDICAL SCIENTIST TRAININGT32GM007308 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 1985 to 2019
$23.2M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
Training Program in Immunology and Inflammation.T32AI100853 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Susan Ruth Schwab · 2012 to 2026
$4.5M
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung CancerR01CA248896 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEEL, BENJAMIN G., WONG, KWOK KIN · 2021 to 2025
$3.4M
Translational Basic and Clinical Research Training in RheumatologyT32AR069515 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jill P Buyon, Jose U. Scher · 2017 to 2026
$2.9M
Elucidating the Role of Cancer-Associated FGL1 in Tumor Immunity and Developing FGL1-Guided Anti-LAG-3 Cancer ImmunotherapyR37CA273333 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JUN WANG · 2022 to 2026
$2.8M
Elucidating the Immune Suppressive Mechanism of SIGLEC-15 in the Tumor MicroenvironmentR01CA269898 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JUN WANG · 2023 to 2026
$2.3M
Dermal Lymphatic Transport and Cutaneous Immune BalanceR01AR080068 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Amanda W. Lund · 2022 to 2026
$2.1M
Machine learning for identifying antigen-antibody interactions from massive sequencing dataR01AI190103 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Junzhou Huang, JUN WANG · 2025 to 2026
$1.3M
HHS | NIH | National Cancer Institute (NCI) P30CA016087HHS | NIH | National Cancer Institute (NCI) R01CA248896HHS | NIH | National Cancer Institute (NCI) R01CA269898HHS | NIH | National Cancer Institute (NCI) R37CA273333HHS | NIH | National Cancer Institute (NCI) T32CA009161HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) T32AI100853HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR080068HHS | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007308Melanoma Research Alliance (MRA) Young Investigator AwardNCI NIH HHS P30 CA016087NCI NIH HHS R01 CA248896NCI NIH HHS R01 CA269898NCI NIH HHS R37 CA273333NCI NIH HHS T32 CA009161NIAID NIH HHS R01 AI190103NIAID NIH HHS T32 AI100853NIAMS NIH HHS R01 AR080068NIAMS NIH HHS T32 AR069515NIGMS NIH HHS T32 GM007308
6 · The paper itself
Abstract
SHP1 (PTPN6) and SHP2 (PTPN11) are closely related protein-tyrosine phosphatases (PTPs), which are autoinhibited until their SH2 domains bind paired tyrosine-phosphorylated immunoreceptor tyrosine-based inhibitory/switch motifs (ITIMs/ITSMs). These PTPs bind overlapping sets of ITIM/ITSM-bearing proteins, suggesting that they might have some redundant functions. By studying T cell-specific single and double knockout mice, we found that SHP1 and SHP2 redundantly restrain naïve T cell differentiation to effector and central memory phenotypes, with SHP1 playing the dominant role. Surprisingly, loss of SHP2 alone in T cells enhanced the antitumor effects of anti-PD-1 antibodies, whereas there was no effect of SHP1 deletion. Also unexpectedly, the absence of both PTPs resulted in poorer tumor control and failure to respond to Programmed Cell Death Protein 1 (PD-1) blockade, associated with reduced frequency and activation of T cells and dendritic cells. Mechanistic studies revealed that CD4
Indexed as
CD4-Positive T-LymphocytesProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6AnimalsCell DeathLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutProgrammed Cell Death 1 ReceptorPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Ptpn11 protein, mousePtpn6 protein, mouseITIMPD-1PTPN11PTPN6tumor immunity
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
T lymphocyte-specific deletion of SHP1 and SHP2 promotes activation-induced cell death of CD4 · full record | OpenQuestion